Liraglutide injection is a clinically proven solution for weight management in overweight adults (BMI≥27) with weight-related health conditions or obese individuals (BMI≥30). As a GLP-1 receptor agonist, it works by slowing gastric emptying and promoting satiety signals in the brain.
The treatment should be administered as part of a comprehensive weight management program that includes reduced calorie intake and increased physical activity. Patients typically start with lower doses that are gradually increased to minimize potential side effects while maximizing therapeutic benefits.
Common side effects may include gastrointestinal symptoms such as nausea, diarrhea, constipation, and vomiting. Some patients may experience headache, fatigue, dizziness, or abdominal discomfort, particularly during the initial adjustment period.
The medication comes in a convenient pen injector format for easy self-administration. Each pen contains multiple doses, making it suitable for daily use as prescribed by healthcare professionals.
For optimal results, patients should maintain regular medical supervision throughout their treatment course to monitor progress, adjust dosage as needed, and manage any side effects that may occur.